Duloxetine Delayed-Release Capsules — Class II drug recall D-0308-2025
Ongoing recall by Breckenridge Pharmaceutical, Inc., reported 2025-04-09, distributed nationwide. CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above
| Recall number | D-0308-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ, United States |
| Recall initiated | 2025-03-26 |
| Classified | 2025-04-01 |
| Reported by FDA | 2025-04-09 |
| Distributed | Nationwide (US) |
| Quantity | 14,863 bottles |
| Reason classes | chemical contamination, cgmp, specification failure |
| NDC | 51991-0746, 51991-0746-05, 51991-0746-06, 51991-0746-90, 51991-0747, 51991-0747-10, 51991-0747-33, 51991-0747-90, 51991-0748, 51991-0748-10, 51991-0748-33, 51991-0748-90, 51991-0750, 51991-0750-05, 51991-0750-10, 51991-0750-33, 51991-0750-90 |
| Lot numbers | 240909C |
| Expiration dates | 2027-03-31 |
Product
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.
Reason for recall
CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0308-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.